Oruka Therapeutics (NASDAQ:ORKA) Announces Quarterly Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17, Zacks reports.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $9.46 on Friday. The firm has a fifty day moving average price of $9.88 and a 200 day moving average price of $15.01. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13. The stock has a market cap of $354.19 million, a PE ratio of -1.51 and a beta of 0.25.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Thursday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Oruka Therapeutics has an average rating of “Buy” and an average price target of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.